329 related articles for article (PubMed ID: 29133778)
1. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Liraglutide Alters Bone Marrow Exosome-Mediated miRNA Signal Pathways in Ovariectomized Rats with Type 2 Diabetes.
Li J; Fu LZ; Liu L; Xie F; Dai RC
Med Sci Monit; 2017 Nov; 23():5410-5419. PubMed ID: 29133778
[TBL] [Abstract][Full Text] [Related]
2. Renoprotective effect of GLP-1 receptor agonist, liraglutide, in early-phase diabetic kidney disease in spontaneously diabetic Torii fatty rats.
Yamada S; Tanabe J; Ogura Y; Nagai Y; Sugaya T; Ohata K; Natsuki Y; Ichikawa D; Watanabe S; Inoue K; Hoshino S; Kimura K; Shibagaki Y; Kamijo-Ikemori A
Clin Exp Nephrol; 2021 Apr; 25(4):365-375. PubMed ID: 33409761
[TBL] [Abstract][Full Text] [Related]
3. Glucagon-like peptide-1 receptor agonist Liraglutide has anabolic bone effects in ovariectomized rats without diabetes.
Lu N; Sun H; Yu J; Wang X; Liu D; Zhao L; Sun L; Zhao H; Tao B; Liu J
PLoS One; 2015; 10(7):e0132744. PubMed ID: 26177280
[TBL] [Abstract][Full Text] [Related]
4. Neurturin and a GLP-1 Analogue Act Synergistically to Alleviate Diabetes in Zucker Diabetic Fatty Rats.
Trevaskis JL; Sacramento CB; Jouihan H; Ali S; Le Lay J; Oldham S; Bhagroo N; Boland BB; Cann J; Chang Y; O'Day T; Howard V; Reers C; Winzell MS; Smith DM; Feigh M; Barkholt P; Schreiter K; Austen M; Andag U; Thompson S; Jermutus L; Coghlan MP; Grimsby J; Dohrmann C; Rhodes CJ; Rondinone CM; Sharma A
Diabetes; 2017 Jul; 66(7):2007-2018. PubMed ID: 28408435
[TBL] [Abstract][Full Text] [Related]
5. Neuroprotective effect of glucagon-like peptide-1 receptor agonist is independent of glycaemia normalization in type two diabetic rats.
Filchenko I; Simanenkova A; Chefu S; Kolpakova M; Vlasov T
Diab Vasc Dis Res; 2018 Nov; 15(6):567-570. PubMed ID: 30024276
[TBL] [Abstract][Full Text] [Related]
6. Exploring the pathogenesis of type 2 diabetes mellitus intestinal damp-heat syndrome and the therapeutic effect of Gegen Qinlian Decoction from the perspective of exosomal miRNA.
He L; Bao T; Yang Y; Wang H; Gu C; Chen J; Zhai T; He X; Wu M; Zhao L; Tong X
J Ethnopharmacol; 2022 Mar; 285():114786. PubMed ID: 34763043
[TBL] [Abstract][Full Text] [Related]
7. Identification of Potential Therapeutic Targets and Pathways of Liraglutide Against Type 2 Diabetes Mellitus (T2DM) Based on Long Non-Coding RNA (lncRNA) Sequencing.
Huang Y; Li J; Chen S; Zhao S; Huang J; Zhou J; Xu Y
Med Sci Monit; 2020 Apr; 26():e922210. PubMed ID: 32238798
[TBL] [Abstract][Full Text] [Related]
8. GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial.
Farr OM; Sofopoulos M; Tsoukas MA; Dincer F; Thakkar B; Sahin-Efe A; Filippaios A; Bowers J; Srnka A; Gavrieli A; Ko BJ; Liakou C; Kanyuch N; Tseleni-Balafouta S; Mantzoros CS
Diabetologia; 2016 May; 59(5):954-65. PubMed ID: 26831302
[TBL] [Abstract][Full Text] [Related]
9. Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review.
Østergaard L; Frandsen CS; Madsbad S
Expert Rev Clin Pharmacol; 2016; 9(2):241-65. PubMed ID: 26573176
[TBL] [Abstract][Full Text] [Related]
10. GLP-1 improves adipose tissue glyoxalase activity and capillarization improving insulin sensitivity in type 2 diabetes.
Rodrigues T; Borges P; Mar L; Marques D; Albano M; Eickhoff H; Carrêlo C; Almeida B; Pires S; Abrantes M; Martins B; Uriarte C; Botelho F; Gomes P; Silva S; Seiça R; Matafome P
Pharmacol Res; 2020 Nov; 161():105198. PubMed ID: 32942016
[TBL] [Abstract][Full Text] [Related]
11. GLP-1 as a target for therapeutic intervention.
Rajeev SP; Wilding J
Curr Opin Pharmacol; 2016 Dec; 31():44-49. PubMed ID: 27591964
[TBL] [Abstract][Full Text] [Related]
12. Long-term liraglutide treatment is associated with increased insulin content and secretion in β-cells, and a loss of α-cells in ZDF rats.
Schwasinger-Schmidt T; Robbins DC; Williams SJ; Novikova L; Stehno-Bittel L
Pharmacol Res; 2013 Oct; 76():58-66. PubMed ID: 23891763
[TBL] [Abstract][Full Text] [Related]
13. Effects of the glucagon-like peptide-1 receptor agonist liraglutide in juvenile transgenic pigs modeling a pre-diabetic condition.
Streckel E; Braun-Reichhart C; Herbach N; Dahlhoff M; Kessler B; Blutke A; Bähr A; Übel N; Eddicks M; Ritzmann M; Krebs S; Göke B; Blum H; Wanke R; Wolf E; Renner S
J Transl Med; 2015 Feb; 13():73. PubMed ID: 25890210
[TBL] [Abstract][Full Text] [Related]
14. Activation of glucagon-like peptide-1 receptor inhibits tumourigenicity and metastasis of human pancreatic cancer cells via PI3K/Akt pathway.
Zhao H; Wang L; Wei R; Xiu D; Tao M; Ke J; Liu Y; Yang J; Hong T
Diabetes Obes Metab; 2014 Sep; 16(9):850-60. PubMed ID: 24641303
[TBL] [Abstract][Full Text] [Related]
15. Glucagon-like peptide 1 receptor agonist ameliorates the insulin resistance function of islet β cells via the activation of PDX-1/JAK signaling transduction in C57/BL6 mice with high-fat diet-induced diabetes.
Hao T; Zhang H; Li S; Tian H
Int J Mol Med; 2017 Apr; 39(4):1029-1036. PubMed ID: 28290604
[TBL] [Abstract][Full Text] [Related]
16. Liraglutide for Type 2 diabetes and obesity: a 2015 update.
Iepsen EW; Torekov SS; Holst JJ
Expert Rev Cardiovasc Ther; 2015; 13(7):753-67. PubMed ID: 26106933
[TBL] [Abstract][Full Text] [Related]
17. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in the Treatment of Obese Women with Polycystic Ovary Syndrome.
Tzotzas T; Karras SN; Katsiki N
Curr Vasc Pharmacol; 2017; 15(3):218-229. PubMed ID: 28003008
[TBL] [Abstract][Full Text] [Related]
18. Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: Post-hoc analyses of four clinical trials.
Tonneijck L; Muskiet MHA; Smits MM; Bjornstad P; Kramer MHH; Diamant M; Hoorn EJ; Joles JA; van Raalte DH
Diabetes Obes Metab; 2018 May; 20(5):1235-1245. PubMed ID: 29341461
[TBL] [Abstract][Full Text] [Related]
19. Activation of Glucagon-Like Peptide-1 Receptor Ameliorates Cognitive Decline in Type 2 Diabetes Mellitus Through a Metabolism-Independent Pathway.
Li Q; Jia M; Yan Z; Li Q; Sun F; He C; Li Y; Zhou X; Zhang H; Liu X; Bu X; Gao P; He H; Zhao Z; Zhu Z
J Am Heart Assoc; 2021 Jul; 10(14):e020734. PubMed ID: 34250817
[TBL] [Abstract][Full Text] [Related]
20. Liraglutide prevents fast weight gain and β-cell dysfunction in male catch-up growth rats.
Zheng J; Chen T; Zhu Y; Li HQ; Deng XL; Wang QH; Zhang JY; Chen LL
Exp Biol Med (Maywood); 2015 Sep; 240(9):1165-76. PubMed ID: 25710926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
